Outcomes of patients with continuous flow left ventricular assist device undergoing emergency endovascular treatment for atraumatic bleeding

CVIR Endovascular

Table 1 Patients cohort with antithrombotic therapy and coagulative profile at the time of bleeding (* second bleeding)

PATIENT N°	AGE (years)	SEX (M/F)	THERAPY (drug (dose))	International Normalized Ratio (INR)	Prothrombin Time (PT) (%)	Activated Partial Thromboplastin Time (APTT) (s)
1	67	M	Warfarin	1,13	64	43
2	43	M	Fondaparinux (5 mg/day)	1,56	38	40
3	49	M	Aspirin (160 mg/day) and Fondaparinux (5 mg/day)	1,28	52	24
4	59	F	Aspirin (100 mg/day) and Fondaparinux (2,5 mg/day)	1,10	67	26
5	63	M	Aspirin (100 mg/day) and Fondaparinux (2,5 mg/day)	1,16	79	28
6	65	M	Fondaparinux (2,5 mg/day)	1,04	94	38
7	53	F	Fondaparinux (2,5 mg/day)	1,09	84	32
7	53	F	Fondaparinux (2,5 mg/day)	1,05*	92*	39*

* indicates the coagulation values of patient 7 during the second bleeding episode